Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 0.8% - Time to Buy?

Key Points

• Armata Pharmaceuticals' stock increased by 0.8% to $2.55, with trading volume significantly up by 26% compared to the average session.
• Wall Street analysts raised the price target for Armata from $7.00 to $9.00 and issued a "buy" rating.
• Institutional investors, including GSB Wealth Management LLC, now hold about 3.57% of Armata Pharmaceuticals' shares, with a recent acquisition of 30,000 shares valued at approximately $57,000.

Shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) rose 0.8% on Friday . The company traded as high as $2.60 and last traded at $2.55. Approximately 11,410 shares were traded during mid-day trading, an increase of 26% from the average daily volume of 9,032 shares. The stock had previously closed at $2.53.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their target price on Armata Pharmaceuticals from $7.00 to $9.00 and gave the company a "buy" rating in a report on Monday, May 19th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $9.00.

Armata Pharmaceuticals Price Performance

The firm has a fifty day moving average price of $2.26. The stock has a market cap of $90.94 million, a PE ratio of -2.44 and a beta of 0.99.

Institutional Investors Weigh In On Armata Pharmaceuticals

A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC purchased a new stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned about 0.08% of Armata Pharmaceuticals at the end of the most recent reporting period. 3.57% of the stock is currently owned by institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.